Parkinson disease, the effect of levodopa, and the ELLDOPA trial

被引:182
作者
Fahn, S [1 ]
机构
[1] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA
关键词
D O I
10.1001/archneur.56.5.529
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The introduction of effective doses of levodopa for the treatment of Parkinson disease (PD)(1,2) was a revolutionary step in overcoming symptoms of a progressive neurodegenerative disease. This took place a little more than 30 years ago, and still, today, levodopa remains the most effective drug for the reversal of symptoms of PD.(1,2) If there were no associated adverse effects with long-term use, treatment of PD would be a simple matter. But most of the physician's effort in providing optimum care of patients with PD is in trying to overcome all too common adverse effects of levodopa.
引用
收藏
页码:529 / 535
页数:7
相关论文
共 105 条
  • [1] Levodopa - Is toxicity a myth?
    Agid, Y
    [J]. NEUROLOGY, 1998, 50 (04) : 858 - 863
  • [2] Alam ZI, 1997, J NEUROCHEM, V69, P1326
  • [3] Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra
    Alam, ZI
    Jenner, A
    Daniel, SE
    Lees, AJ
    Cairns, N
    Marsden, CD
    Jenner, P
    Halliwell, B
    [J]. JOURNAL OF NEUROCHEMISTRY, 1997, 69 (03) : 1196 - 1203
  • [4] Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors
    Alexander, T
    Sortwell, CE
    Sladek, CD
    Roth, RH
    SteeceCollier, K
    [J]. CELL TRANSPLANTATION, 1997, 6 (03) : 309 - 315
  • [5] Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys
    Arai, N
    Isaji, M
    Kojima, M
    Mizuta, E
    Kuno, S
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1996, 103 (11) : 1307 - 1316
  • [6] PERMANENT HUMAN PARKINSONISM DUE TO 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) - 7 CASES
    BALLARD, PA
    TETRUD, JW
    LANGSTON, JW
    [J]. NEUROLOGY, 1985, 35 (07) : 949 - 956
  • [7] Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease
    Blanchet, PJ
    Papa, SM
    Metman, LV
    Mouradian, MM
    Chase, TN
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1997, 21 (04) : 447 - 453
  • [8] DOES LEVODOPA AGGRAVATE PARKINSONS-DISEASE
    BLIN, J
    BONNET, AM
    AGID, Y
    [J]. NEUROLOGY, 1988, 38 (09) : 1410 - 1416
  • [9] SUPPRESSIVE EFFECT OF L-DOPA ON DOPAMINE CELLS REMAINING IN THE VENTRAL TEGMENTAL AREA OF RATS PREVIOUSLY EXPOSED TO THE NEUROTOXIN 6-HYDROXYDOPAMINE
    BLUNT, SB
    JENNER, P
    MARSDEN, CD
    [J]. MOVEMENT DISORDERS, 1993, 8 (02) : 129 - 133
  • [10] CALNE DB, 1969, LANCET, V1, P744